This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
J&J ETFs to Shine Bright as FDA Grants EUA for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Johnson & Johnson's receipt of EUA for its single-shot COVID-19 vaccine will strengthen the U.S. government's position in the fight against the pandemic and benefit ETFs with high exposure to the pharmaceutical giant.
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
Pfizer's Coronavirus Vaccine Gets a Nod in UK: ETFs to Shine
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
What Lies Ahead for Pfizer ETFs After Another Round of Upbeat Vaccine Data
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in the coronavirus vaccine development.
J&J Pauses Coronavirus Vaccine Trial: ETFs That May Take a Hit
by Sweta Jaiswal, FRM
Johnson & Johnson's pausing of dosing in all clinical studies on its coronavirus vaccine candidate has increased uncertainty surrounding the coronavirus vaccine development.
JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus
by Sweta Killa
Despite solid results and an upbeat view, shares of JNJ dropped as the company halted its final-phase of clinical trials for its COVID-19 vaccine candidate.
ETFs in Focus on Momenta Buyout Deal With JNJ
by Sweta Killa
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
JNJ Beats, Cuts View on Coronavirus: Healthcare ETFs in Focus
by Sweta Killa
Investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker post its earnings release.